News: ZLD Zelda Therapeutics Posts HY Comprehensive Loss For Period Of $2.6 Mln, page-47

You know im rediculasly heavy on zelda/zelira and i dont doubt the team has a good chance of delivering on some of its promises this year

product launches, some revenues, progressed trials

but will it have that desired effect for investors ... im starting to think all too little to late ...

yes i think they will deliver no i dont think its getting any significant rerate

they have had there chance

you could have thrown a dart at any one of the companies with in this space over the last 3 years and seen at least one up trend rerate ... except this one.

if the market was interested in clinically validated or distribution channels, or revenues (AND IT WAS A YEAR AGO) it would have recognized any one of the significant milestones achieced by zelira to date ... and it hasnt

i must ask my self why

and i must also ask what makes any one think if after achieving world first statistically significant, clinical validation, global manufacturing and distribution, even maiden revenues through whats proposed as only the first licencing deal of the so many on offer through the US and the world ...

if after all that the markets looked at this and dictated ita price.

my question is who or what can justify any future deliverables being recieved any differently?

seriously